Baidu
map

Cell:激活APC基因可诱导结直肠癌细胞转变为正常的细胞

2015-06-19 MedSci译 MedSci原创

Science Daily:癌症治疗的新希望——激活某特定的基因可诱导肿瘤细胞转变为正常的细胞抗癌治疗通常包括杀死肿瘤细胞,然而,据6月18日发表在Cell上的一项研究表明,仅通过激活一个单一的基因就可以诱导癌细胞转为正常的组织。研究人员发现,恢复成正常细胞的人结直肠癌细胞在小鼠体内停止生长并在短短4天内重新建立起正常的肠道功能。值得注意的是,两周内肿瘤消失,数月后也未有肿瘤复发的迹象。该发现为修




抗癌治疗通常包括杀死肿瘤细胞,然而,据6月18日发表在Cell上的一项研究表明,仅通过激活一个单一的基因就可以诱导癌细胞转为正常的组织。研究人员发现,恢复成正常细胞的人结直肠癌细胞在小鼠体内停止生长并在短短4天内重新建立起正常的肠道功能。值得注意的是,两周内肿瘤消失,数月后也未有肿瘤复发的迹象。该发现为修复肿瘤抑制基因的功能可引起肿瘤的消失提供证据,并为未来癌症的有效治疗提供方向。

结直肠癌是发达国家癌症相关死亡的第二大因素,全世界每年约700000人患结直肠癌死亡。“晚期结直肠癌的治疗方案通常联合化疗,但是化疗的毒性很大,而且化疗的效果并不理想,然而在过去的十年里结直肠癌的治疗方法并未有重大的突破。”来自纪念斯隆凯特林癌症中心的高级研究员Scott Lowe说道。

高达90%的结直肠癌细胞内含有的结肠腺瘤样息肉基因(Apc)突变,虽然普遍认为此种突变导致了大肠癌的的发生,但是目前尚未清楚Apc灭活在肿瘤生长过程中是否也发挥了作用。

“我们想知道在肿瘤发生的过程中纠正Apc突变是否足以阻断肿瘤的发生并诱导肿瘤细胞转变回正常细胞,”该研究的第一作者Lukas Dow说道。由于在试图恢复功能缺失或突变的基因时往往会激活其他的基因,使得正常细胞发生问题,因此很难解决纠正突变基因的问题。

为了克服这个难题,Lowe以及他的团队利用基因技术在已建立的新的结直肠癌模型的大鼠身上准确可逆的破坏了Apc的活性。目前大多数动物结直肠癌肿瘤模型的肿瘤主要发生在小肠,而Lowe等所建立的新的模型中,还诱导了结肠肿瘤的发生,使得模型与人结直肠更加相似。与以往的研究结果一致,Apc抑制激活Wnt信号通路,这就是大众普遍所知的控制细胞的增殖,迁移和存活。
Apc激活后,Wnt信号恢复到正常水平,肿瘤细胞停止增殖,肠细胞恢复正常的功能。两周内肿瘤变小,消失或变回正常的细胞,而且在6个月的随访期间并未发现肿瘤复发的迹象。此外,该方法可有效地治疗含 Kras 和 p53突变(人结直肠癌患者中约半数含有此突变)的恶性结直肠癌肿瘤小鼠。

“识别肿瘤特异性基因突变是世界上很多实验室研究的重点,”Dow说道,“如果我们能够确定哪种类型的突变或变化可诱导肿瘤的发生,那么我们将能更好的确定癌症个体最佳的治疗方案。”

Lowe和他的团队将研究肿瘤细胞中Apc活化后的后果,他们还会继续研究为什么Apc能有效的一直结直肠癌肿瘤的生长,以期未来的某一天药物治疗也可模仿这种作用。

“目前若想直接修复大肠患者的Apc功能是不切实际的,过去的证据表明,完全阻断Wnt信号通路很可能会对正常肠细胞引起剧毒,”Lowe说道,“然而,我们的研究发现表明,旨在调节而不是阻断Wnt信号通路的小分子可能达到与Apc活化相似的效果。仍需进一步的研究以确定WNT抑制或类似的方法是否可为临床提供长远的治疗价值。”

原始出处:

Single gene turns colorectal cancer cells back into normal tissue in mice

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-07-26 DocterSunshine

    老基因新观点

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-09-29 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 erhong

    高明

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 summer474cn

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 summer474cn

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 summer474cn

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1805753, encodeId=8d1d1805e53fb, content=<a href='/topic/show?id=95e7e87031b' target=_blank style='color:#2F92EE;'>#结直肠癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78703, encryptionId=95e7e87031b, topicName=结直肠癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Sep 13 04:20:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869145, encodeId=fa421869145e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 03:20:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33508, encodeId=fd473350805, content=老基因新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc1635944, createdName=DocterSunshine, createdTime=Sun Jul 26 13:19:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959399, encodeId=74b4195939942, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 29 19:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29169, encodeId=f881291697a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28549, encodeId=6d582854901, content=高明, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:16:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28468, encodeId=d91328468b6, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28469, encodeId=0d4e2846934, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28470, encodeId=bc5b284e078, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28466, encodeId=daa82846637, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 21 16:36:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 summer474cn

    0

相关资讯

Cell:癌症类器官生物银行

 研究人员利用由癌症患者肿瘤衍生出的三维(3D)类器官,接近复制出了原发肿瘤的一些关键特性。这些“类器官”培养物适用于大规模的药物筛查来检测与药物敏感性相关的一些遗传改变,为采用个体化治疗改善癌症患者的临床结局铺平了道路。他们将这项研究发表在5月7日的《细胞》(Cell)杂志上。直到现在,人们还主要是利用培养皿中的二维细胞系或是在小鼠模型中开展抗癌药物筛查。比细胞系更加近似人类肿瘤,且比

Clin Cancer Res:GAPDH或PPOX可能成为结直肠癌治疗的新型化疗靶标

目的:结直肠癌患者临床管理的大大改善是由于对新靶标如EGFR和VEGF的识别。因为肿瘤的快速增殖与患者的不良预后有关,这里我们确定快速增殖的结直肠癌细胞的转录信号特征,试图确定新型候选的治疗靶标。实验设计:对52个结直肠癌细胞系的倍增时间进行确定,采用微阵列分析对这些线性子集的全基因组表达进行评估。然后我们调研快速增长的肿瘤细胞潜在基因高表达的作为新的治疗靶标。结果:快速增长率与微标记物的不稳定性

NEJM:TAS-102对难治性转移性结直肠癌的临床效果

背景:主要在日本进行的早期临床试验已经表明,抗癌药物TAS-102(一种结合三氟胸苷和地匹福林盐酸盐的口服剂)对于难治性大肠癌的治疗是有效的。研究人员进行了3期临床试验以进一步评估在全球范围内TAS-102对病人的功效和安全性。    方法:在这个双盲研究中,研究人员以2:1的比例随机分配800例患者,分别接受TAS-102或安慰剂。主要终点是总生存期。 

Cancer Discov.:新型Sym004 抗-EGFR抗体混合物用于难治性结直肠癌的临床研究

背景:在表皮生长因子受体(EGFR)抑制剂的抵抗下肿瘤生长可能保持EGFR-依从性,其是通过补偿性的配体上调和新创基因突变进行介导的。Sym004是靶标为非重叠EGFR抗原的两个抗体混合物。临床试验:在临床前模型中,Sym004可使EGFR显著的内化和降解,在配体的存在下转化为更上一级的生长抑制作用。在临床I期试验阶段,剂量升级期间,我们观察到基于机制的剂量限制反应:3级皮肤毒性和低镁血症。在剂量

Int J Epidemiol:女性身高越高,患结直肠癌的风险越大

Int J Epidemiol:女性身高越高,患结直肠癌的风险越大近日有研究表明,身高与女性结直肠的发生有关,该研究与2015年3月20日在线发表于Int J Epidemiol.无论男性还是女性,身高越高其发生癌症的风险越高。对于结直肠癌(CRC)目前还不清楚不同性别的身高差异是其发生的直接因素,混杂因素亦或者是观察性研究中的偏倚。本研究中,我们采用孟德尔随机化研究以评估身高与CDC发生风险之间

JAMA:高质量的结肠镜筛查可降低死亡率

近期发表在JAMA的新研究发现,通过结肠镜筛查发现更多的腺瘤可以使一生中结直肠癌的发生风险和死亡风险降低50%-60%,而并不需要花费更多的费用。“腺瘤检查率(ADR)被推荐作为结肠镜检查质量指示因子。”该研究的主要作者、荷兰Erasmus MC大学医学中心的Reinier G. S. Meester如是说,“然而,ADR与基于结肠镜的结直肠癌筛查带来的长期获益及花费的关系,目前尚不明确。”为了评

Baidu
map
Baidu
map
Baidu
map